| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Commercial Officer
1 company
Mottiwala Aziz serves as a Chief Commercial Officer at TARS. Across recent SEC filings that breaks down to 0 buys and 25 sells. Those positions are worth an estimated $4.1M at current prices.
Historically, Mottiwala Aziz's trades have earned a middling insider score of 51/100 across 21 rated trades. Over a 12-month horizon, 25.0% of those trades were profitable, with an average 12-month return of -42.1%.
The biggest single holding is TARS (~$4.1M) as Chief Commercial Officer. The recent filings there lean toward selling, a net 72,591 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 15, 2022 | TARS Tarsus Pharmaceuticals, Inc. | Chief Commercial Officer | Sell | 6,857 | $17.72 | $121,506.04 | -12.1% | -15.1% | +0.7% | |
| Nov 8, 2021 | TARS Tarsus Pharmaceuticals, Inc. | Chief Commercial Officer | Sell | 1,889 | $28.11 | $53,099.79 | -3.6% | -38.9% | -35.6% | |
| Nov 5, 2021 | TARS Tarsus Pharmaceuticals, Inc. | Chief Commercial Officer | Sell | 111 | $28.04 | $3,112.21 | -0.2% | -39.2% | -35.5% | |
| Nov 2, 2021 | TARS Tarsus Pharmaceuticals, Inc. | Chief Commercial Officer | Sell | 6,000 | $26.78 | $160,690.36 | -10.3% | -24.8% | -34.6% | |
| Sep 10, 2021 | TARS Tarsus Pharmaceuticals, Inc. | Chief Commercial Officer | Sale+OE | 2,593 | $22.15 | $57,434.95 | -4.3% | +8.2% | -27.8% |